Evaluation of reproductive and renal toxicity of varenicline in male rats

Document Type: Original Article

Authors

1 Inonu University, School of Medicine, Department of Urology, Malatya, Turkey

2 Inonu University, School of Medicine, Department of Histology and Embryology, Malatya, Turkey

3 Inonu University, School of Medicine, Department of Pharmacology, Malatya, Turkey

4 Malatya State Hospital, Department of Internal Medicine, Malatya, Turkey

5 Inonu University, School of Medicine, Department of Physiology, Malatya, Turkey

6 Inonu University, School of Medicine, Department of Family Medicine, Malatya, Turkey

Abstract

Objective(s): Varenicline is a selective partial agonist for the nicotinic acetylcholine receptor a4b2 subtype, which is widely used to treat smoking addiction. However, there is still no data about its potential toxic effects on tissues. In this study, we aimed to determine the varenicline-induced toxicity on reproductive and renal tissues in rats.
Materials and Methods: Rats were randomly divided into two groups: control (n=10) and varenicline (n=24). Then, rats in each group were sub-divided equally as acute and chronic groups. The control rats were orally given distilled water only. Varenicline was administrated orally as follows: 1st–3rd days 9 µg/kg/day, 4th–7th days 9 µg/kg twice daily, and 8th–90th days 18 µg/kg twice daily. The rats of acute and chronic groups were sacrificed on the 45th and 90th days, respectively. Some tissue markers related to oxidative stress were measured, and sperm characteristics were observed.
Results: In the acute group, varenicline led to a significant decrease in SOD activities in both kidney and testis tissues. In the chronic group, varenicline significantly increased MDA and MPO production, and reduced CAT and GPx levels in the kidneys and testes. Also, SOD and GSH levels significantly decreased in the testes. Moreover, sperm characteristics were negatively affected; histopathological deformation was observed in the testes and kidneys in all groups.
Conclusion: This study showed that varenicline could detrimentally affect the kidneys and testes in both acute and chronic term usage. Further studies will provide more insights into the molecular dynamics of this damage.

Keywords


1. McNeil JJ, Piccenna L, Ioannides-Demos LL. Smoking cessation recent advances. Cardiovasc. Drug Ther 2010;24:359-67.
2. Wang C, Cho B, Xiao D, Wajsbrot D, Park PW. Effectiveness and safety of varenicline as an aid to smoking cessation: results of an inter-Asian observational study in real-world clinical practice. Int J Clin Pract 2013;67:469-476.
3. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2008;16:CD006103.
4. Kaur K, Kaushal S, Chopra SC. Varenicline for smoking cessation: a review of the literature. Curr Ther Res Clin Exp 2009;70:35-54.
5. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011;183:1359-1366.
6. Colak C, Parlakpinar H. Reporting In Vivo Experiments: ARRIVE Guidelines-Review. J Turgut Ozal Med Cent 2012;19:128-131.
7. Sharma V, McNeill JH. To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 2009;157:907-921.
8. Uchiyama M, Mihara M. Determination of MDA precursor in tissue by TBA test. Anal Biochem 1978;36: 271-278.
9. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 1968;25:192-205.
10. Sun Y, Oberley LW, Li YA. Simple method for clinical assay of superoxide dismutase. Clin Chem 1988;34:497-500.
11. Aebi H. Catalase.  In: Bergmeyer HU (ed) In methods of enzymatic analysis. New York, NY: Academic Press 1974;673-677.
12. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967;70:158-169.
13. Wei H, Frenkel K. Relationship of oxidative events and DNA oxidation in Sencar mice to in vivo promoting activity of phorbol ester-type tumor promoters. Carcinogenesis 1993;14:1195-1201.
14. Ciftci O, Aydin M, Ozdemir I, Vardi N. Quercetin prevents 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced testicular damage in rats. Andrologia 2012;44:164-173.
15. West R, Baker CL, Cappelleri JC, Bushmakin AG. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms,and rewarding effects of smoking during a quit attempt. Psychopharmacology 2008;197:371-377.
16. Bolin K, Mark AC, Willers S, Lindgren B. Varenicline as compared to bupropion in smoking-cessation therapy-Cost-utilityresults for Sweden 2003. Respir Med 2008;102:699-710.
17. Coe JW, Brooks PR, Vetelino MG, Coe JW, Brooks PR, Vetelino MG, et al. Varenicline:An alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005;48:3474-3477.
18. Dougherty PL. Varenicline: A new pharmaceutical approach to smoking cessation. Nurs Womens Health 2008;12:66-69.
19. Bird ML, Vesta KS. Varenicline-associated acute renal failure. The Annals of Pharmacotherapy 2008;42:1908-1911.
20. Koç A, Erken HA, Koçak FE, Yay A, Güçlü A, Sari E, et al. Nephrotoxic effects of varenicline as the most effective drug used for smoking cessation: a preliminary experimental study. Int Urol Nephrol 2015;47:823-829.
21. Woynillowicz AK, Raha S, Nicholson CJ, Holloway AC. The effect of smoking cessation pharmacotherapies on pancreatic beta cell function. Toxicol Appl Pharmacol 2012;265:122-127.
22. Ozbek E, Turkoz Y, Sahna E, Ozugurlu F, Mizrak B, Ozbek M. Melatonin administration prevents the nephrotoxicity induced by gentamicin. BJU Int 2000;85:742-6.
23. Parlakpinar H, Ozer MK, Sahna E, Vardi N, Cigremis Y, Acet A. Amikacin-induced acute renal injury in rats protective role of melatonin. J Pineal Res 2003;35:85-90.
24. Walker EM, Gale GR. Methods of reduction of cisplatin nephrotoxicity. Ann Clin Lab Sci 1981;11:397-410.
25. Parlakpinar H, Olmez E, Acet A, Ozturk F, Tasdemir S, Ates B, et al. Beneficial effects of apricot-feeding on myocardial ischemia-reperfusion injury in rats. Food Chem Toxicol 2009;49: 802-808.
26. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994;94:437-444.
27. Wieland E, Brandes A, Armstrong VW, Oellerich M. Oxidative modification of low density lipoproteins by human polymorphonuclear leukocytes. Eur J Clin Chem Clin Biochem 1993;31:725-731.
28. Sahna E, Parlakpinar H, Ozturk F, Cigremis Y, Acet A. The protective effects of physiological and pharmacological concentrations of melatonin on renal ischemia-reperfusion injury in rats. Urol Res 2003;31:188-193.
29. Brüne B, von Knethen A, Sandau KB. Nitric oxide and its role in apoptosis. Eur J Pharmacol 1998;26;351:261-272.
30. Richburg JH. The relevance of spontaneous and chemically induced alterations in testicular germ cell apoptosis to toxicology. Toxicol. Lett. 2000;112-113:79-86.
31. Hegazy R, Salama A, Mansour D, Hassan A. Renoprotective Effect of Lactoferrin against Chromium-Induced Acute Kidney Injury in Rats: Involvement of IL-18 and IGF-1 Inhibition. PLoS One 2016;18;11:e0151486.